News from Zyme and the companies we work with.
Owlstone Medical Secures $6.5 Million to Support Development of Breath-based Diagnostics for Infectious Disease
$5 million equity investment and initial $1.5 million grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the developing [...]
CN Bio raises $21 million USD in first close of Series B investment round
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively Investment will expand product development and scaling of the organization to meet increased demand for [...]
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance
First senior executive appointment made following Company launch to oversee strategic development of clinical programs Oslo, Norway, 23 April 2024: Calluna Pharma (Calluna), a clinical stage company pioneering a breakthrough [...]
Neurolentech Signs Technology Access Partnership with Kaerus Bioscience to Advance Neurodevelopmental Disorder Research
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes Klosterneuburg, Austria, 22 April 2024: Neurolentech, a pioneering drug [...]
Zyme Communications expands UK head office with new facilities at Cambridge Innovation Park
Investment in new headquarters forms part of ongoing company growth plans and supports Zyme’s continued success, following client base and team expansion Cambridge, UK, 17 April 2024: Zyme Communications Ltd., [...]
Sphere Fluidics appoints Edward Rayner as Non-Executive Director
Ed Rayner joins Sphere Fluidics as new board member to strengthen the Company’s strategic vision and ambition for commercial growth Cambridge, UK, 17 April, 2024: Sphere Fluidics, a leading provider [...]
Bio-Rad Announces Collaboration Agreement with Oncocyte to Commercialize Transplant Monitoring with Droplet Digital PCR
Collaboration Aims to Provide Researchers Cutting-Edge Tools to Enable Transformational Monitoring of Key Biomarkers in Solid Tissue Transplants HERCULES, Calif.— April 12, 2024 — Bio-Rad Laboratories, Inc. (NYSE: BIO and [...]
Metrion Biosciences enhances High Throughput Screening services with access to Enamine compound libraries
Access to compound collection enables greater flexibility and efficiencies in screening and target identification Cambridge, UK and Kyiv, Ukraine, 11 April 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel [...]
OBN Invites Life Science R&D Companies, Industry Leaders, Academics, and Investors to BioTrinity 2024
New, larger venue of Convene 133 Houndsditch, central London, offers increased capacity, additional partnering space, improved networking opportunities, and a dual track of R&D showcase opportunities Programme features keynote from [...]
Preci and Biopredic International partner for higher performance of suspended pooled hepatocytes with extended longevity and large-scale availability
License agreement extends access to culture-stable pooled hepatocyte cell models with increased longevity for use in DMPK and ADME studies Kyiv, Ukraine, and Rennes, France, 10 April 2024: Preci, a [...]
Bio-Rad and Allegheny Health Network Cancer Institute Collaborate to Advance Personalized Monitoring of Solid Tumor Cancers with Droplet Digital PCR
Collaboration Aims to Grow Clinical Evidence Supporting the use of Bio-Rad’s ddPCR™ Technology for Molecular Residual Disease Monitoring of Patients across a Range of Solid Tumor Types HERCULES, Calif., and [...]
Bio-Rad Launches First Ultrasensitive Multiplexed Digital PCR Assay for Breast Cancer Mutation Detection in Clinical Research
Highly Sensitive and Multiplexed Assay for the Detection, Discrimination, and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600™ Droplet Digital™ PCR System HERCULES, Calif. [...]